CD28 and cancer: In general, samples from R groups showed more enriched pathways related to inflammasomes, interferon gamma signaling, cancer immunotherapy by PD-1 blockade, T cell receptor and co-stimulatory signaling, IL-12 signaling mediated by STAT4, and co-stimulation by the CD28 family.